Companies › Terrestrial Bio
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VX-201 GLP-1 receptor agonist delivered via microneedle array patch | GLP1R | Phase 1 | Overweight and/or Obesity | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07673900 | VX-201 | Phase 1 | Overweight and/or Obesity | Metabolic and endocrine | Feb 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.